Skip to main content
Clinical Trials/NCT01592162
NCT01592162
Completed
Phase 4

Dose-effect of Propofol for Anesthetic Induction: Double-blind Comparison of Different Propofol Formulations Administered Alone or With Remifentanil

Hopital Foch2 sites in 1 country409 target enrollmentMay 2013

Overview

Phase
Phase 4
Intervention
Propofol (Astra-Zeneca), NaCl 0.9%
Conditions
Anesthesia
Sponsor
Hopital Foch
Enrollment
409
Locations
2
Primary Endpoint
necessary dose of propofol to obtain the induction of anesthesia (defined by a bispectral index < 60 over 30 continuous seconds)
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The objective of this study is to evaluate the influence of different propofol formulations (plain or with remifentanil) on anesthetic induction. Propofol plain or with remifentanil is administered using a closed-loop algorithm in order to reach a Bispectral Index target of 50.

Registry
clinicaltrials.gov
Start Date
May 2013
End Date
November 2014
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients scheduled for an intravenous induction of anesthesia with propofol

Exclusion Criteria

  • Age under 18
  • Pregnancy or breastfeeding
  • Allergy to propofol, soya or peanuts,
  • Allergy to remifentanil,
  • History of central neurological disorder or brain injury,
  • Patients receiving psychotropic drugs,
  • Patient with a pacemaker

Arms & Interventions

propofol 1% (Astra-Zeneca) - remi 0

propofol 1% (Astra-Zeneca)plus remifentanil 0 ng/ml

Intervention: Propofol (Astra-Zeneca), NaCl 0.9%

propofol 1% (Astra-Zeneca) - remi 2

propofol 1% (Astra-Zeneca)plus remifentanil 2 ng/ml

Intervention: propofol 1% (Astra-Zeneca) and remifentanil

propofol 1% (Astra-Zeneca) - remi 4

propofol 1% (Astra-Zeneca)plus remifentanil 4 ng/ml

Intervention: propofol 1% (Astra-Zeneca) and remifentanil

propofol 1% (Fresenius) - remi 0

propofol 1% (Fresenius) plus remifentanil 0 ng/ml

Intervention: Propofol (Astra-Zeneca), NaCl 0.9%

propofol 1% (Fresenius) - remi 2

propofol 1% (Fresenius) plus remifentanil 2 ng/ml

Intervention: Propofol (Astra-Zeneca) and remifentanil

propofol 1% (Fresenius) - remi 4

propofol 1% (Fresenius) plus remifentanil 4 ng/ml

Intervention: Propofol (Astra-Zeneca) and remifentanil

propofol 1% (B-Braun) - remi 0

propofol 1% (B-Braun) plus remifentanil 0 ng/ml

Intervention: Propofol (B-Braun) and NaCl 0.9%

propofol 1% (B-Braun) - remi 2

propofol 1% (B-Braun) plus remifentanil 2 ng/ml

Intervention: Propofol (B-Braun) and remifentanil

propofol 1% (B-Braun) - remi 4

propofol 1% (B-Braun) plus remifentanil 4 ng/ml

Intervention: Propofol (B-Braun) and remifentanil

Outcomes

Primary Outcomes

necessary dose of propofol to obtain the induction of anesthesia (defined by a bispectral index < 60 over 30 continuous seconds)

Time Frame: one hour after anesthesia

Secondary Outcomes

  • pain at injection(one hour after anesthesia)
  • patient's satisfaction(one day after anesthesia)
  • calculated concentrations of propofol at the end of the anesthetic induction(one hour after anesthesia)
  • Disappearance of the eyelash reflex(One hour after anesthesia)
  • heart rate modifications induced by anesthetic induction(one hour after anesthesia)
  • arterial pressure modifications induced by anesthetic induction(one hour after anesthesia)

Study Sites (2)

Loading locations...

Similar Trials